Phio Pharmaceuticals CorpFRA Phio Stock Report

Phio Pharmaceuticals Corp. is a biotechnology company engaged in the development of immuno-oncology therapeutics that addresses unmet medical needs. The company is headquartered in Marlborough, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2012-05-10. The firm is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL-based therapeutics are used to strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT) and directly modify cells in the tumor microenvironment (the TME) to weaken a tumors defense. Its lead product candidate is PH-762, which is an INTASYL compound that activates immune cells to better recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1, a clinically validated target for immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression that impacts cell differentiation, and hence, cell function. The company is also developing PH-804, which targets the suppressive immune receptor TIGIT.